Chr. Hansen probiotics show positive effect on preterm babies

Chr. Hansen’s probiotic strains Bifidobacterium lactis BB-12^?, Streptococcus thermophilus TH-4 and Bifidobacterium infantis BB-02, were used in a new study to test their effects on premature babies, according to a report posted on the company’s website. Coordinated by Associate Professor Sue Jacobs and Professor Suzanne Garland at the Royal Women's Hospital in Melbourne, Australia, the study was done specifically on 1,1000 infants with necrotizing enterocolitis (NEC), a serious condition, where parts of the intestine may undergo tissue death.

“It is a very well-designed, large-scale study and I consider this extremely strong data within an important indication,” according to Chr. Hansen’s Dorte Eskesen, senior scientific advisor, Health & Nutrition Division. “I am impressed that the study team managed to conduct a study of this size in vulnerable infants in neonatal intensive care units”  

The randomised, double-blind, placebo-controlled, multicentre study showed convincing results, according to Chr. Hansen. “We have a strong focus on infant health and support research initiatives that will enable us to make continuous advancements,” said Christian Barker, executive vice president, Health & Nutrition Division. “The study findings are remarkable. From a commercial point of view, however, NEC is a small area compared to other indications such as functional bowel disorders and diarrhea. Nonetheless, it is encouraging receiving this type of confirmation that Chr. Hansen’s probiotics make a difference for such a serious condition as NEC.”

According to a report in Neonatology, 6-7 per cent of premature babies in neonatal intensive care units can be affected by NEC and approx. 25 per cent of babies with the condition don't survive¹. (Photo © tan4ikk I 123 RF Stock Photos)